Lyndra Therapeutics’ investigational oral, weekly opioid use disorder treatment LYN-014 granted fast track designation by FDA

Lyndra Therapeutics

27 July 2021 - LYN-014 has the potential to address significant public health concerns about access to opioid use disorder treatment and reduce patients’ need for daily methadone administration.

Lyndra Therapeutics today announced that LYN-014, the company’s oral, ultra long-acting, extended release levomethadone capsule in development for the weekly treatment of opioid use disorder, has received fast track designation from the U.S. FDA.

Read Lyndra Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track